Compare PGC & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PGC | EVMN |
|---|---|---|
| Founded | 1921 | 2020 |
| Country | United States | United States |
| Employees | N/A | 48 |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 698.4M | 825.5M |
| IPO Year | 1997 | N/A |
| Metric | PGC | EVMN |
|---|---|---|
| Price | $41.37 | $22.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $40.50 | ★ $43.88 |
| AVG Volume (30 Days) | 102.5K | ★ 288.0K |
| Earning Date | 04-22-2026 | 06-11-2026 |
| Dividend Yield | ★ 0.48% | N/A |
| EPS Growth | ★ 13.51 | N/A |
| EPS | ★ 0.80 | N/A |
| Revenue | ★ $282,995,000.00 | N/A |
| Revenue This Year | $32.39 | N/A |
| Revenue Next Year | $12.64 | N/A |
| P/E Ratio | $52.28 | ★ N/A |
| Revenue Growth | ★ 24.05 | N/A |
| 52 Week Low | $24.45 | $13.89 |
| 52 Week High | $43.83 | $33.20 |
| Indicator | PGC | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 55.90 | 42.32 |
| Support Level | $32.44 | $21.39 |
| Resistance Level | $43.83 | $23.08 |
| Average True Range (ATR) | 1.48 | 1.56 |
| MACD | -0.29 | -0.20 |
| Stochastic Oscillator | 39.95 | 20.44 |
Peapack Gladstone Financial Corp is a bank holding company. Through its subsidiaries, the company offers various wealth management, investment banking, and commercial and personal banking solutions to its clients. The company has two reportable segments: Banking, which generates the maximum revenue, and Wealth Management. The Banking segment includes commercial, commercial real estate, multifamily, residential, and consumer lending activities; treasury management services; escrow management; deposit generation; operation of ATMs; telephone and internet banking services; credit card services, etc. The Wealth Management segment offers investment management services for individuals and institutions; personal trust services; and other financial planning and advisory services.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.